Why the study?
While obesity rates are increasing worldwide, the optimal dosage for obese patients has not been established for most anticoagulants.
What is the optimal dosage of anticoagulants (LMWH, NOAC, and fondaparinux) in obese patients?
Population
72 studies in obese patients (BMI ≥ 30 kg/m2 or body weight ≥ 100 kg)
Comparison
Dosage of LMWH, NOAC, and fondaparinux
Design
Systematic review
Authors
Loading...
May guide LMWH dosing in bariatric surgery for BMI ≥40; extends evidence supporting standard NOAC doses in obese VTE/AF patients.
What is the optimal dosage of anticoagulants (LMWH, NOAC, and fondaparinux) in obese patients?
This systematic review provides specific dosage recommendations for LMWH, NOACs, and fondaparinux in obese patients requiring thromboprophylaxis or treatment for VTE or AF.
Abildgaard et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: